FORT WORTH, Texas, Nov. 27, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing…
NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor, a clinically validated target for the treatment…
Conference call today at 8:30 am ETVANCOUVER, British Columbia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a…
Athyrium Provides Capital to Support Long-Term Growth and Exchanges Outstanding Debt into Equity of Certain Reorganized Entities RVL Pharmaceuticals plc…
Chimeric Bait Receptor-programmed macrophages show promise for treatment of Non-Hodgkin LymphomaLONDON, UK / ACCESSWIRE / November 27, 2023 / Hemogenyx…
Booth (#7326) will highlight new product introductions, key innovations, and AI-enabled advancements from the company’s comprehensive portfolio of Imaging, Ultrasound,…
TeleDaaS revolutionizes radiopharmaceutical research by delivering highly-scalable, clinical-grade dosimetry to accelerate cancer treatment breakthroughsCHICAGO, Nov. 26, 2023 (GLOBE NEWSWIRE) --…
BBS-Bioactive Bone Substitutes Plc, press release, 25 November 2023 at 11.00 a.m. BBS-Bioactive Bone Substitutes Plc ("BBS") has received confirmation…
Niagara Falls, NY, Nov. 24, 2023 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular…
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR…